Navigation Links
Greater representation of elderly patients in Phase III trials are needed
Date:2/22/2013

DENVER The median age of patients diagnosed with advanced nonsmall-cell lung cancer (NSCLC) has steadily increased over the recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented in clinical trials. A recent study published in the March 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, investigated the degree to which exclusion or underrepresentation of elderly occurs in practice-changing clinical trials in advanced NSCLC. Researchers conclude that greater representation of elderly patients in phase III trials is required to better define evidence-based paradigms in the increasingly elderly NSCLC population.

Researchers did an extensive literature search, included articles for review if they were phase III, involved systemic therapy alone, studied advanced NSCLC and were conducted between 1980 and 2010. A total of 248 studies were identified and their full text reviewed by the authors.

Among the 100 most cited trials, 33 percent excluded elderly patients in their trial design. The average reported median patient age in those trials was 60.9 years.

The authors "have clearly demonstrated that a significant proportion of highly cited phase III clinical trials in advanced NSCLC overtly exclude elderly patients." They recommend that a greater emphasis be placed on recruiting clinical trial patients with age demographics that better represent the median age of the advanced NSCLC population.


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related medicine news :

1. Bullied Children at Greater Risk for Self-Harm, Study Finds
2. Greater numbers of highly educated women are having children, bucking recent history
3. Irregular Heartbeat Poses Greater Stroke Risk for Women Than Men
4. Hepatitis C Causing Liver Damage in Greater Numbers: Study
5. Unemployed Americans face greater risk of mortality: UBC study
6. Greater L.A. Heating Up, Climate Experts Predict
7. Greater availability of neurosurgeons could reduce risk of death from motor vehicle accidents
8. Early treatment could mean greater earning potential for people with HIV
9. Men Have a Greater Lifetime Risk for Kidney Failure: Study
10. More Friends, Greater Well-Being at Midlife?
11. Ancestral link places Mexican-Americans at greater risk for metabolic disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... Immune Pharmaceuticals Inc. (NASDAQ: IMNP ), ... has filed a patent application directed to the treatment ... --> --> The new invention ... (histamine dihydrochloride) in combination with immune checkpoint inhibitors. The ... of Ceplene and IL-2 therapy in patients with Acute ...
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology: